Brock Reeve
Harvard University
23 Papers
92 Citations
Brock Reeve is an academic researcher from Harvard University. The author has contributed to research in topics: Stem cell & Stock market. The author has an hindex of 11, co-authored 20 publications.
Chat about Author
Papers
Shattering barriers toward clinically meaningful MSC therapies.
Oren Levy,Rui Kuai,Rui Kuai,Erika M. J. Siren,Deepak Bhere,Yuka Milton,Nabeel Nissar,Michael De Biasio,Martina Heinelt,Brock Reeve,Reza Abdi,Meshael Alturki,Mohanad Fallatah,Abdulaziz Almalik,Ali H. Alhasan,Khalid Shah,Khalid Shah,Jeffrey M. Karp +17 more
TL;DR: The major clinical challenges with MSC therapies, the details of these challenges, and the potential bioengineering approaches that leverage the unique biology of MSCs to overcome the challenges and achieve more potent and versatile therapies are discussed.
540
Generating iPSCs: Translating Cell Reprogramming Science into Scalable and Robust Biomanufacturing Strategies
Marli Silva,Laurence Daheron,Hannah Hurley,Kim Bure,Richard J. Barker,Andrew Carr,Andrew Carr,David J. Williams,Hae-Won Kim,Anna French,Peter J. Coffey,Peter J. Coffey,Justin J. Cooper-White,Justin J. Cooper-White,Brock Reeve,Mahendra Rao,Evan Y. Snyder,Kelvin S. Ng,Kelvin S. Ng,Kelvin S. Ng,Benjamin E. Mead,Benjamin E. Mead,Benjamin E. Mead,James A. Smith,James A. Smith,Jeffrey M. Karp,Jeffrey M. Karp,Jeffrey M. Karp,David Brindley,Ivan Wall,Ivan Wall +30 more
TL;DR: The need to define standardized practices foriPSC generation and processing is highlighted and current challenges to the robust manufacture of iPSC products are discussed.
64
Enabling Consistency in Pluripotent Stem Cell-Derived Products for Research and Development and Clinical Applications Through Material Standards
Anna French,Christopher A. Bravery,James R. Smith,Amit Chandra,Peter R.T. Archibald,Joseph D. Gold,Natalie Artzi,Hae-Won Kim,Richard W. Barker,Alexander Meissner,Joseph C. Wu,Jonathan C. Knowles,David J. Williams,Guillermo García-Cardeña,Doug Sipp,Steve Oh,Jeanne F. Loring,Mahendra S. Rao,Brock Reeve,Ivan B. Wall,Andrew Carr,Kim Bure,Glyn Stacey,Jeffrey M. Karp,Evan Y. Snyder,David Brindley +25 more
TL;DR: The need for reference materials (RMs) is outlined and the approaches to in‐house RM generation for hPSC‐derived products are assessed, a critical tool for the analysis and control of product variation that can be applied by researchers and developers.
36
The global cell therapy industry continues to rise during the second and third quarters of 2012.
Chris Mason,Mark J.S. McCall,Emily J. Culme-Seymour,Shalini Suthasan,S Edwards-Parton,Gregory A. Bonfiglio,Brock Reeve +6 more
TL;DR: During Q2-Q3 2012, the cell therapy industry benefited from a number of positive external influences including advantageous changes to future FDA regulation, but stock market activity was highly mixed.
30
Quantitative assessment of barriers to the clinical development and adoption of cellular therapies: A pilot study.
Benjamin Davies,Sarah Rikabi,Anna French,Rafael Pinedo-Villanueva,Mark E. Morrey,Karolina Wartolowska,Andrew Judge,Robert E MacLaren,Anthony Mathur,David J. Williams,Ivan Wall,Martin A. Birchall,Brock Reeve,Anthony Atala,Richard W. Barker,Zhanfeng Cui,Dominic Furniss,Kim Bure,Evan Y. Snyder,Jeffrey M. Karp,Andrew Price,Andrew Carr,David Brindley +22 more
TL;DR: A pilot study to survey clinicians from five specialities and to determine what they believe to be the most significant barriers to cellular therapy clinical development and adoption shows that the main concerns among this group are cost-effectiveness, efficacy, reimbursement, and regulation.